Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride‐induced liver fibrosis

Liver fibrosis is a common pathway leading to cirrhosis. Cilostazol, a clinically available oral phosphodiesterase‐3 inhibitor, has been shown to have antifibrotic potential in experimental non‐alcoholic fatty liver disease. However, the detailed mechanisms of the antifibrotic effect and its efficacy in a different experimental model remain elusive.

• Publication year

  2014

• Venue

  Hepatology Research

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/hepr.12140PMID 23607402
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THERAPEUTIC TARGETS OF ALPD AND CIRRHOSIS Novel anti-fibrotic modalities for liver fibrosis: Molecular targeting and regenerative medicine in fibrosis therapy

  2012cited by this paper
• Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia.

  2012cited by this paper
• Reticulon 4B (Nogo‐B) is a novel regulator of hepatic fibrosis

  2011cited by this paper
• The N-terminal domain of human hemokinin-1 influences functional selectivity property for tachykinin receptor neurokinin-1.

  2011cited by this paper
• (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R.

  2009cited by this paper
• Assessment of buccal absorption of cilostazol 100-mg orally disintegrated tablets in healthy adult male subjects

  2009cited by this paper
• Bioequivalence study of cilostazol 100-mg orally disintegrated tablets and cilostazol 100-mg conventional tablets in healthy adult male subjects

  2009cited by this paper
• Mechanisms of hepatic fibrogenesis.

  2008cited by this paper
• Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease

  2008cited by this paper
• Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo

  2007cited by this paper
• Pro-fibrogenic potential of PDGF-D in liver fibrosis.

  2007cited by this paper
• Local Inhibition of Liver Fibrosis by Specific Delivery of a Platelet-Derived Growth Factor Kinase Inhibitor to Hepatic Stellate Cells

  2007cited by this paper
• Hepatic stellate cell protrusions couple platelet‐derived growth factor‐BB to chemotaxis

  2007cited by this paper
• TLR4 enhances TGF-beta signaling and hepatic fibrosis.

  2007cited by this paper
• Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

  2006cited by this paper
• LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice.

  2006cited by this paper
• Mechanisms of liver fibrosis.

  2006cited by this paper
• Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use

  2006cited by this paper
• Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice

  2005cited by this paper
• Anandamide induces necrosis in primary hepatic stellate cells

  2005cited by this paper
• Attenuated liver fibrosis in the absence of B cells.

  2005cited by this paper
• Isolation and culture of hepatic stellate cells.

  2005cited by this paper
• Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.

  2005cited by this paper
• Evaluation of Liver Fibrosis: A Concise Review

  2004cited by this paper
• Regulation of PDGF and its receptors in fibrotic diseases.

  2004cited by this paper
• Cilostazol and Dipyridamole Synergistically Inhibit Human Platelet Aggregation

  2004cited by this paper
• Liver fibrosis -- from bench to bedside.

  2003cited by this paper
• Cilostazol as a unique antithrombotic agent.

  2003cited by this paper
• Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell.

  2003cited by this paper
• [Mechanisms of hepatic fibrogenesis].

  2002cited by this paper
• The role of Smad3 in mediating mouse hepatic stellate cell activation

  2001cited by this paper
• Interplay Between Inhibition of Adenosine Uptake and Phosphodiesterase Type 3 on Cardiac Function by Cilostazol, an Agent to Treat Intermittent Claudication

  2001cited by this paper
• Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis

  2001cited by this paper
• Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21.

  2000cited by this paper
• Application of tyramide signal amplification system to immunohistochemistry: A potent method to localize antigens that are not detectable by ordinary method

  1999cited by this paper
• Cytokine regulation of hepatic stellate cells in liver fibrosis.

  1999cited by this paper
• OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.

  1999cited by this paper
• Platelet-derived Growth Factor-BB and Thrombin Generate Positive and Negative Signals for Human Hepatic Stellate Cell Proliferation

  1998cited by this paper
• Proliferation of hepatic stellate cells is inhibited by phosphorylation of CREB on serine 133.

  1997cited by this paper
• Inhibition of myofibroblastic transformation of cultured rat hepatic stellate cells by methylxanthines and dibutyryl cAMP

  1996cited by this paper
• Effect of cilostazol on the production of platelet-derived growth factor in cultured human vascular endothelial cells.

  1996cited by this paper
• Growth inhibitory properties of endothelin-1 in activated human hepatic stellate cells: a cyclic adenosine monophosphate-mediated pathway. Inhibition of both extracellular signal-regulated kinase and c-Jun kinase and upregulation of endothelin B receptors.

  1996cited by this paper
• [Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase--assessment of its effect on coagulation and fibrinolytic parameters].

  1994cited by this paper
• Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture.

  1994cited by this paper
• Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells.

  1993cited by this paper
• Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic neuropathy.

  1992cited by this paper
• Insights into the pathogenesis of alcoholic liver necrosis and fibrosis: Status report

  1990cited by this paper
• Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors.

  1989cited by this paper
• Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan.

  1987cited by this paper
• Effect of cilostazol on platelet aggregation and experimental thrombosis.

  1985cited by this paper

• Cilostazol-inhibited RhoA/NF-κB signaling mitigates hippocampal inflammation and post-stroke depression

  2025cites this paper
• Possible Role of Platelets in the Development and Progression of Non-Alcoholic Fatty Liver Disease.

  2025cites this paper
• Repurposing of Antiplatelet Agent: Cilostazol for the Treatment of Alcohol-Related Liver Disease

  2025cites this paper
• Investigation of the protective effect of cilostazol on acute lung injury-mediated inflammation and in silico molecular modelling studies of inflammatory signalling pathway: a repurposing study

  2025cites this paper
• Combined carvacrol and cilostazol ameliorate ethanol-induced liver fibrosis in rats: Possible role of SIRT1/Nrf2/HO-1 pathway.

  2023cites this paper
• Platelets in Non-alcoholic Fatty Liver Disease

  2022cites this paper
• Cilostazol Attenuates AngII-Induced Cardiac Fibrosis in apoE Deficient Mice

  2022cites this paper
• Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression

  2021cites this paper
• Cilostazol protects rats against alcohol-induced hepatic fibrosis via suppression of TGF-β1/CTGF activation and the cAMP/Epac1 pathway.

  2019cites this paper
• Role of Nrf2/HO-1 and PI3K/Akt Genes in the Hepatoprotective Effect of Cilostazol.

  2019cites this paper
• Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers

  2019cites this paper
• Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.

  2018cites this paper
• Beneficial effects of cilostazol on liver injury induced by common bile duct ligation in rats: Role of SIRT1 signaling pathway

  2018cites this paper
• The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis.

  2017cites this paper
• Role of hemostatic factors in hepatic injury and disease: animal models de‐liver

  2016cites this paper
• Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis

  2016cites this paper
• Neuroprotective Effects of Simvastatin and Cilostazol in l-Methionine-Induced Vascular Dementia in Rats

  2016cites this paper
• Pulmonary, gastrointestinal and urogenital pharmacologyCilostazol attenuates cholestatic liver injury and its complications in common bile duct ligated rats

  2015cites this paper
• The significance of YKL-40 protein in liver fibrosis

  2014cites this paper
• The phosphodiesterase 3 inhibitor cilostazol does not stimulate growth of colorectal liver metastases after major hepatectomy

  2014cites this paper
• Die Wirkung des Phosphodiesterase-3-Inhibitors Cilostazol auf das Tumorwachstum von kolorektalen Lebermetastasen nach ausgedehnter Leberteilresektion

  2014cites this paper